Table 4.
Relative risk of second primary cancer by type of first primary cancer and time period of first diagnosis, Queensland, 1982-2006
| Time period of first diagnosis | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1982-1986 | 1987-1991 | 1992-1996 | 1997-2001 | |||||
| First primary cancer | Obs. |
SIR (95% CI) |
Obs. |
SIR (95% CI) |
Obs. |
SIR (95% CI) |
Obs. |
SIR (95% CI) |
| Head and neck | 165 |
1.92 (1.64-2.23) |
204 |
1.88 (1.63-2.16) |
271 |
1.98 (1.75-2.23) |
255 |
1.93 (1.70-2.18) |
| Oesophagus | 8 | 1.53 (0.66-3.02) |
10 | 0.90 (0.43-1.66) |
23 |
1.60 (1.01-2.39) |
23 | 1.19 (0.76-1.79) |
| Stomach | 18 | 0.75 (0.44-1.18) |
27 | 1.02 (0.67-1.49) |
30 | 0.91 (0.62-1.31) |
36 | 1.09 (0.76-1.51) |
| Colorectal | 198 | 0.89 (0.77-1.02) |
273 | 0.95 (0.84-1.07) |
411 | 1.07 (0.97-1.18) |
559 |
1.20 (1.11-1.31) |
| Pancreas | 7 | 1.20 (0.48-2.47) |
5 | 0.61 (0.20-1.42) |
10 | 0.98 (0.47-1.81) |
12 | 0.83 (0.43-1.45) |
| Lung | 71 | 1.06 (0.83-1.34) |
93 | 1.14 (0.92-1.40) |
147 |
1.61 (1.36-1.89) |
148 |
1.30 (1.10-1.53) |
| Melanoma | 311 |
1.81 (1.62-2.02) |
471 |
1.89 (1.72-2.07) |
639 |
2.04 (1.88-2.20) |
835 |
2.02 (1.89-2.16) |
| Breast - female | 152 | 0.97 (0.82-1.14) |
199 | 0.94 (0.81-1.08) |
359 |
1.32 (1.19-1.47) |
504 |
1.37 (1.25-1.50) |
| Cervix | 24 | 1.29 (0.83-1.92) |
38 |
1.88 (1.33-2.58) |
34 |
1.64 (1.14-2.29) |
26 |
1.55 (1.01-2.27) |
| Uterus | 30 | 1.14 (0.77-1.63) |
35 | 1.18 (0.82-1.64) |
35 | 0.87 (0.60-1.21) |
63 | 1.30 (0.99-1.66) |
| Ovary | 16 | 1.36 (0.78-2.20) |
10 | 0.64 (0.31-1.18) |
26 | 1.35 (0.88-1.98) |
24 | 1.02 (0.66-1.52) |
| Prostate | 163 |
0.64 (0.54-0.74) |
291 |
0.76 (0.68-0.85) |
603 |
0.84 (0.77-0.91) |
655 | 0.95 (0.88-1.02) |
| Kidney | 44 |
1.48 (1.08-1.99) |
73 |
1.79 (1.40-2.25) |
92 |
1.53 (1.24-1.88) |
160 |
2.04 (1.74-2.38) |
| Bladder | 137 |
1.46 (1.22-1.72) |
189 |
1.78 (1.53-2.05) |
238 |
1.84 (1.61-2.09) |
353 |
2.22 (2.00-2.47) |
| Brain & CNS | -- | -- | 5 | 1.00 (0.33-2.34) |
-- | -- | 9 | 1.10 (0.50-2.09) |
| Thyroid | 9 | 1.25 (0.57-2.38) |
12 | 1.25 (0.64-2.18) |
29 |
1.64 (1.10-2.36) |
46 |
1.67 (1.22-2.23) |
| Non-Hodgkin lymphoma | 42 | 1.09 (0.79-1.48) |
62 | 1.15 (0.88-1.48) |
88 |
1.25 (1.00-1.54) |
144 |
1.49 (1.25-1.75) |
| Lymphoid leukaemia | 24 | 1.00 (0.64-1.48) |
33 | 1.25 (0.86-1.75) |
63 |
1.68 (1.29-2.15) |
88 |
1.71 (1.37-2.10) |
| Myeloid leukaemia | 13 | 1.23 (0.66-2.11) |
11 | 0.91 (0.45-1.62) |
26 | 1.52 (0.99-2.22) |
34 |
2.05 (1.42-2.86) |
| Myeloma/PCT | 21 | 1.37 (0.85-2.10) |
7 |
0.46 (0.19-0.95) |
19 | 0.83 (0.50-1.29) |
39 | 1.05 (0.75-1.44) |
| Other | 79 | 0.94 (0.74-1.17) |
136 |
1.22 (1.03-1.45) |
241 |
1.43 (1.26-1.62) |
318 |
1.43 (1.28-1.60) |
| All cancers combined | 1,534 |
1.14 (1.08-1.20) |
2,184 |
1.22 (1.17-1.28) |
3,386 |
1.36 (1.31-1.41) |
4,331 |
1.46 (1.41-1.50) |
Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; CNS = central nervous system; PCT = plasma cell tumours. Analysis by period of first diagnosis was restricted to five years of follow-up to allow more consistent comparisons across time. SIRs shown in normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk. Estimates are not shown for Brain & CNS for the periods 1982-1986 and 1992-1996 due to observed cell counts of less than 5.